NEXT event in the partnering series
Accelerate collaboration and partnering across neurology and psychiatry pipelines and technologies, to reduce risk, validate technologies, and deliver better biodistribution of safe and efficacious molecules to the CNS
this event has run!
returning in 2025
Advance clinical efficacy and commercial success of targeted cell depletion and immune tolerance technologies for Autoimmune Disease
ATTENDed in 2024
Why Autoimmunity Partnering Summit?
More Targeted
United C-level and Business Development with aligned strategic and scientific interests across tolerance and targeted cell depletion, to increase interactions with a volume of viable partners.
Earlier Opportunity
People work with people, and with partnerships often delayed by not finding and building a relationship with the right individual sooner, you met the right contacts from buyers scouting earlier pipeline opportunities, sooner.
With Scientific Insights
Evaluated competitive landscapes, assessed where your research fits within the broader landscape, and met with synergistic researchers to share risks through collaboration with complementary projects.
Size of the Networking Opportunity
Total Audience Networking
Creating Alignment Through Targeted Critical Mass: With a shared focus on scientific interests and partnering goals, attendees enjoyed more meaningful interactions, free from distractions. This led to higher-quality conversations, better engagement, and significantly improved follow-up opportunities
Individual Meetings: One-on-One Partnering™
Partnering Portal: Using the same partnering portal as BIO, searched attendees and pre-scheduled meetings into calendars ahead of the conference, with meetings automatically linked to a private meeting space.
Why THIS summit?
The unprecedented clinical efficacy and investment generated by Candid Therapeutics' $370M debut has positioned TCE antibodies in the race with cell therapies, as targeted B cell depletion takes on the clinical efficacy and commercial success of Humira.
Combined with immune tolerization to rebuild a less aberrant immune system through engineered Tregs and antigen-specific immune tolerance; immune reset and reconstitution will change treatment paradigms dramatically.
But, despite this dynamic macroenvironment, the average biotech-pharma collaboration takes over a year, and with pharma receiving >700 invitations to connect at large conferences; not meeting the right contact in person is elongating biotech deal-making.
The Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind, laying enabled partnering on top of hyper-relevant scientific discussion so that pharma can contextualize and compare, and biotech can have guaranteed face-to-face meetings with key contacts specific to immunology deal-making.
EXPERT SPEAKERS in 2024 INCLUDEd
Chris Gagliardi
Principal
Sanofi Ventures
Nicola La Monica
Senior Director, Strategic Search & Evaluation
Johnson & Johnson
Swarna Balasubramanian
Associate Director, Search & Evaluation Respiratory & Immunology
AstraZeneca
Melissa Matzelle
Director, Immunology Search & Evaluation
AbbVie
Emma Smith
Head of Immune Reset
UCB
Testimonials
“This was a brilliant opportunity to connect with potential partners and hear meaningful talks and discussions relevant to the space."
“The event assembled a diverse set of stakeholders extremely relevant in ADC & RLT partnering, including pharma BD, investors, and biotech executives. It was the right size (~100 attendees) that created organic opportunities for connections”
OTHER HANSON WADE SUMMITS
